Skip to main content
NCBI home page
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 1992 Dec;85(12):752–756. doi: 10.1177/014107689208501213

Pancytopenia related to azathioprine--an enzyme deficiency caused by a common genetic polymorphism: a review.

A Anstey 1, L Lennard 1, S C Mayou 1, J D Kirby 1
PMCID: PMC1293765  PMID: 1494166

Full text

PDF
752

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacon B. R., Treuhaft W. H., Goodman A. M. Azathioprine-induced pancytopenia. Occurrence in two patients with connective-tissue diseases. Arch Intern Med. 1981 Feb;141(2):223–226. [PubMed] [Google Scholar]
  2. Denman E. J., Denman A. M., Greenwood B. M., Gall D., Heath R. B. Failure of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis. Ann Rheum Dis. 1970 May;29(3):220–231. doi: 10.1136/ard.29.3.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ginzler E., Sharon E., Diamond H., Kaplan D. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum. 1975 Jan-Feb;18(1):27–34. doi: 10.1002/art.1780180106. [DOI] [PubMed] [Google Scholar]
  4. Goadsby P. J., Day R. O., Kwan Y. L., Miners J., Birkett D. J. 6-Mercaptopurine-related leucopenia and in vivo xanthine oxidase activity. Lancet. 1986 Oct 11;2(8511):869–870. doi: 10.1016/s0140-6736(86)92911-9. [DOI] [PubMed] [Google Scholar]
  5. Grant D. M., Tang B. K., Campbell M. E., Kalow W. Effect of allopurinol on caffeine disposition in man. Br J Clin Pharmacol. 1986 Apr;21(4):454–458. doi: 10.1111/j.1365-2125.1986.tb05222.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Guerciolini R., Szumlanski C., Weinshilboum R. M. Human liver xanthine oxidase: nature and extent of individual variation. Clin Pharmacol Ther. 1991 Dec;50(6):663–672. doi: 10.1038/clpt.1991.205. [DOI] [PubMed] [Google Scholar]
  7. Haas J., Patzold U. Uber die Blutbildveränderungen bei langfristiger Behandlung der Multiplen Sklerose und Myasthenie mit Azathioprin. Nervenarzt. 1982 Feb;53(2):105–109. [PubMed] [Google Scholar]
  8. Hall B. M., Tiller D. J., Horvath J. S., Duggin G. G., Johnson J. R., Roy L. P., Hurley B., Harris J. P., Rogers J. R., Stephen M. S. Treatment of renal transplantation rejection. Cyclosporin A versus conventional treatment with azathioprine, prednisone and antithymocyte immunoglobulin in primary cadaveric renal transplantation. Med J Aust. 1985 Feb 4;142(3):179–185. [PubMed] [Google Scholar]
  9. Hohlfeld R., Michels M., Heininger K., Besinger U., Toyka K. V. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology. 1988 Feb;38(2):258–261. doi: 10.1212/wnl.38.2.258. [DOI] [PubMed] [Google Scholar]
  10. Jeurissen M. E., Boerbooms A. M., van de Putte L. B. Pancytopenia related to azathioprine in rheumatoid arthritis. Ann Rheum Dis. 1988 Jun;47(6):503–505. doi: 10.1136/ard.47.6.503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kissel J. T., Levy R. J., Mendell J. R., Griggs R. C. Azathioprine toxicity in neuromuscular disease. Neurology. 1986 Jan;36(1):35–39. doi: 10.1212/wnl.36.1.35. [DOI] [PubMed] [Google Scholar]
  12. Kvien T. K., Høyeraal H. M., Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol. 1986 Feb;13(1):118–123. [PubMed] [Google Scholar]
  13. Kölle G. Knochenmarksschädigung bei immunsuppressiver Therapie der juvenilen rheumatoiden Arthritis und des Still-Syndroms mit Azathioprin. Dtsch Med Wochenschr. 1969 Oct 31;94(44):2268–2273. doi: 10.1055/s-0028-1110429. [DOI] [PubMed] [Google Scholar]
  14. Lawson D. H., Lovatt G. E., Gurton C. S., Hennings R. C. Adverse effects of azathioprine. Adverse Drug React Acute Poisoning Rev. 1984 Autumn;3(3):161–171. [PubMed] [Google Scholar]
  15. Lennard L. Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr. 1987 Dec 25;423:169–178. doi: 10.1016/0378-4347(87)80340-7. [DOI] [PubMed] [Google Scholar]
  16. Lennard L., Harrington C. I., Wood M., Maddocks J. L. Metabolism of azathioprine to 6-thioguanine nucleotides in patients with pemphigus vulgaris. Br J Clin Pharmacol. 1987 Feb;23(2):229–233. doi: 10.1111/j.1365-2125.1987.tb03034.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lennard L., Lilleyman J. S., Van Loon J., Weinshilboum R. M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990 Jul 28;336(8709):225–229. doi: 10.1016/0140-6736(90)91745-v. [DOI] [PubMed] [Google Scholar]
  18. Lennard L., Murphy M. F., Maddocks J. L. Severe megaloblastic anaemia associated with abnormal azathioprine metabolism. Br J Clin Pharmacol. 1984 Feb;17(2):171–172. doi: 10.1111/j.1365-2125.1984.tb02333.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lennard L., Van Loon J. A., Lilleyman J. S., Weinshilboum R. M. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther. 1987 Jan;41(1):18–25. doi: 10.1038/clpt.1987.4. [DOI] [PubMed] [Google Scholar]
  20. Lennard L., Van Loon J. A., Weinshilboum R. M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989 Aug;46(2):149–154. doi: 10.1038/clpt.1989.119. [DOI] [PubMed] [Google Scholar]
  21. Lorenzen I., Brun C., Videbaek A. Treatment of immunologic diseases with cytostatics. Acta Med Scand. 1969 Jun;185(6):501–506. doi: 10.1111/j.0954-6820.1969.tb07375.x. [DOI] [PubMed] [Google Scholar]
  22. Maddocks J. L., Lennard L., Amess J., Amos R., Thomas R. M. Azathioprine and severe bone marrow depression. Lancet. 1986 Jan 18;1(8473):156–156. doi: 10.1016/s0140-6736(86)92291-9. [DOI] [PubMed] [Google Scholar]
  23. Mertens H. G., Hertel G., Reuther P., Ricker K. Effect of immunosuppressive drugs (azathioprine). Ann N Y Acad Sci. 1981;377:691–699. doi: 10.1111/j.1749-6632.1981.tb33767.x. [DOI] [PubMed] [Google Scholar]
  24. Nossent J. C., Swaak A. J. Pancytopenia in systemic lupus erythematosus related to azathioprine. J Intern Med. 1990 Jan;227(1):69–72. doi: 10.1111/j.1365-2796.1990.tb00121.x. [DOI] [PubMed] [Google Scholar]
  25. O'Donoghue D. P., Dawson A. M., Powell-Tuck J., Bown R. L., Lennard-Jones J. E. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet. 1978 Nov 4;2(8097):955–957. doi: 10.1016/s0140-6736(78)92524-2. [DOI] [PubMed] [Google Scholar]
  26. Odlind B., Hartvig P., Lindström B., Lönnerholm G., Tufveson G., Grefberg N. Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. Int J Immunopharmacol. 1986;8(1):1–11. doi: 10.1016/0192-0561(86)90067-6. [DOI] [PubMed] [Google Scholar]
  27. Pollak R., Nishikawa R. A., Mozes M. F., Jonasson O. Azathioprine-induced leukopenia--clinical significance in renal transplantation. J Surg Res. 1980 Sep;29(3):258–264. doi: 10.1016/0022-4804(80)90169-9. [DOI] [PubMed] [Google Scholar]
  28. Present D. H., Korelitz B. I., Wisch N., Glass J. L., Sachar D. B., Pasternack B. S. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980 May 1;302(18):981–987. doi: 10.1056/NEJM198005013021801. [DOI] [PubMed] [Google Scholar]
  29. Sauer H., Hantke U., Wilmanns W. Azathioprine lymphocytotoxicity. Potentially lethal damage by its imidazole derivatives. Arzneimittelforschung. 1988 Jun;38(6):820–824. [PubMed] [Google Scholar]
  30. Singleton J. W., Law D. H., Kelley M. L., Jr, Mekhjian H. S., Sturdevant R. A. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology. 1979 Oct;77(4 Pt 2):870–882. [PubMed] [Google Scholar]
  31. Taguchi H., Yoshimoto S., Machida K., Yorimitsu Y., Niiya K., Shiomi F., Ueda N. [A case of megaloblastic anemia induced by azathioprine (author's transl)]. Rinsho Ketsueki. 1980 May;21(5):660–664. [PubMed] [Google Scholar]
  32. Verhelst J. A., Van den Enden E., Mathys R. Rapidly evolving azathioprine induced pancytopenia. J Rheumatol. 1987 Aug;14(4):862–862. [PubMed] [Google Scholar]
  33. Weinshilboum R. M., Raymond F. A., Pazmiño P. A. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta. 1978 May 2;85(3):323–333. doi: 10.1016/0009-8981(78)90311-x. [DOI] [PubMed] [Google Scholar]
  34. Weinshilboum R. M., Sladek S. L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980 Sep;32(5):651–662. [PMC free article] [PubMed] [Google Scholar]
  35. Whisnant J. K., Pelkey J. Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities. Ann Rheum Dis. 1982;41 (Suppl 1):44–47. doi: 10.1136/ard.41.suppl_1.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Witte A. S., Cornblath D. R., Schatz N. J., Lisak R. P. Monitoring azathioprine therapy in myasthenia gravis. Neurology. 1986 Nov;36(11):1533–1534. doi: 10.1212/wnl.36.11.1533. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES